UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review of trials currently testing treatment and prevention of COVID-19

Clinical microbiology and infection, 2020-08, Vol.26 (8), p.988-998

2020

Volltextzugriff (PDF)

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

CPT: pharmacometrics and systems pharmacology, 2017-02, Vol.6 (2), p.87-109

2017

Volltextzugriff (PDF)

The Use of Model-Based Tumor-Size Metrics to Predict Survival

Clinical pharmacology and therapeutics, 2014-08, Vol.96 (2), p.133-135

2014

Volltextzugriff (PDF)

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features

Clinical microbiology and infection, 2011-04, Vol.17 (4), p.557-565

2011

Volltextzugriff (PDF)

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients

Clinical pharmacology and therapeutics, 2012-11, Vol.92 (5), p.575-583

2012

Volltextzugriff (PDF)

High acquisition rate of extended-spectrum β-lactamase-producing Enterobacteriaceae among French military personnel on mission abroad, without evidence of inter-individual transmission

Clinical microbiology and infection, 2019-05, Vol.25 (5), p.631.e1-631.e9

2019

Volltextzugriff (PDF)

Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa

CPT: pharmacometrics and systems pharmacology, 2014-12, Vol.3 (12), p.1-4

Mentré, F

2014

Volltextzugriff (PDF)

Determinants of macroscopic anal cancer and precancerous lesions in 1206 HIV-infected screened patients

Colorectal disease, 2016-10, Vol.18 (10), p.997-1004

2016

Volltextzugriff (PDF)

Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-Effects Modeling

Clinical pharmacology and therapeutics, 2012-02, Vol.91 (2), p.234-242

2012

Volltextzugriff (PDF)

Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses

Clinical microbiology and infection, 2014-12, Vol.20 (12), p.O1035-O1041

2014

Volltextzugriff (PDF)

The ISoP Standards and Best Practices Committee

Clinical pharmacology and therapeutics, 2014-06, Vol.95 (6), p.581-582

2014

Volltextzugriff (PDF)

A Pharmacokinetic-Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response

Clinical pharmacology and therapeutics, 2014-11, Vol.96 (5), p.599-608

2014

Volltextzugriff (PDF)

Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008–2009 winter

Clinical microbiology and infection, 2013-02, Vol.19 (2), p.196-203

2013

Volltextzugriff (PDF)

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

CPT: pharmacometrics and systems pharmacology, 2013-06, Vol.2 (6), p.1-2

2013

Volltextzugriff (PDF)

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study

The European respiratory journal, 2012-03, Vol.39 (3), p.772-775

2012

Volltextzugriff (PDF)

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

CPT: pharmacometrics and systems pharmacology, 2014-04, Vol.3 (4), p.1-9

2014

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Variability of Fluindione in Octogenarians

Clinical pharmacology and therapeutics, 2012-05, Vol.91 (5), p.777-786

2012

Volltextzugriff (PDF)

Best Practices in Population Modeling Should Always Be Evolving

CPT: pharmacometrics and systems pharmacology, 2013-07, Vol.2 (7), p.1-2

2013

Volltextzugriff (PDF)

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

CPT: pharmacometrics and systems pharmacology, 2015-06, Vol.4 (6), p.316-319

2015

Volltextzugriff (PDF)

Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome

CPT: pharmacometrics and systems pharmacology, 2013-07, Vol.2 (7), p.1-9

2013

Volltextzugriff (PDF)

A Model‐Based Illustrative Exploratory Approach to Optimize the Dosing of Peg‐IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy

CPT: pharmacometrics and systems pharmacology, 2015-01, Vol.4 (1), p.37-40

2015

Volltextzugriff (PDF)

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV‐infected patients

HIV medicine, 2004-07, Vol.5 (4), p.307-313

2004

Volltextzugriff (PDF)

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study: Table 1

The European respiratory journal, 2012-03, Vol.39 (3), p.772-775

2012

Volltextzugriff (PDF)

Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2: Clin Pharmacol Ther

Clinical pharmacology and therapeutics, 2020, Vol.108 (2)

2020

Volltextzugriff (PDF)

Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients

Clinical pharmacology and therapeutics, 1998-01, Vol.63 (1), p.64-78

1998

Volltextzugriff (PDF)

1 – 25 von 44

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

Zeitschrift / SerieBritish Journal Of Clinical Pharmacology

ThemaPhysical Sciences

KollektionWiley Online Library Journals Frontfile Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(43)

Publikationsform

Artikel
(42)
Tagungsberichte
(2)

Sprache

Englisch
(44)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Review of trials currently testing treatment and prevention of COVID-19

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

The Use of Model-Based Tumor-Size Metrics to Predict Survival

Bacteraemia caused by third-generation cephalosporin-resistant Escherichia coli in France: prevalence, molecular epidemiology and clinical features

Effect of Adherence as Measured by MEMS, Ritonavir Boosting, and CYP3A5 Genotype on Atazanavir Pharmacokinetics in Treatment-Naive HIV-Infected Patients

High acquisition rate of extended-spectrum β-lactamase-producing Enterobacteriaceae among French military personnel on mission abroad, without evidence of inter-individual transmission

Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa

Determinants of macroscopic anal cancer and precancerous lesions in 1206 HIV-infected screened patients

Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-Effects Modeling

Escherichia coli bacteraemia in pregnant women is life-threatening for foetuses

The ISoP Standards and Best Practices Committee

A Pharmacokinetic-Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response

Factors associated with clinical and virological response in patients treated with oseltamivir or zanamivir for influenza A during the 2008–2009 winter

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

Pharmacokinetic and Pharmacodynamic Variability of Fluindione in Octogenarians

Best Practices in Population Modeling Should Always Be Evolving

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome

A Model‐Based Illustrative Exploratory Approach to Optimize the Dosing of Peg‐IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV‐infected patients

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study: Table 1

Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2: Clin Pharmacol Ther

Population pharmacokinetic-pharmacodynamic analysis of fluindione in patients

Aktive Filter

Suchergebnisse filtern